|
One Step Dementia Risk Test Kit
Early screening for Alzheimer’s has long been invasive and costly. A new Chinese-made lateral flow test, using urine instead of CSF or blood, could shift the paradigm for mass population screening.
The One Step Dementia Risk Test Kit is a rapid IVD screening device that detects amyloid-beta (Aβ) concentration in urine, the hallmark biomarker for Alzheimer’s disease. Using colloidal gold lateral immunochromatography, it returns a result in ten minutes from a four-drop sample of midstream urine.
The clinical performance data is concrete: sensitivity of 79.14%, specificity of 91.03%, and a Kappa value of 0.704. These figures place it squarely as an auxiliary screening tool—not a definitive diagnostic—but one that can flag risk early enough to trigger follow-up before irreversible cognitive decline sets in.
It carries CE, NMPA, and MDA certifications, indicating it has passed regulatory scrutiny in Europe and China. The target demographic is individuals aged 45 and older, particularly those with family history of dementia, cardiovascular disease, or lifestyle risk factors like smoking and chronic sleep deprivation.
What makes this product noteworthy from a supply-chain perspective is its reliance on a proprietary Aβ monoclonal antibody and an antibody-polymer sandwich method developed in-house. This means the manufacturer controls the key reagent—a strategic advantage in a diagnostic category where raw material bottlenecks frequently constrain production.
For hospital procurement teams and health screening centers, the operational friction removed here is substantial. No phlebotomy, no cold-chain transport for CSF samples, no specialized lab equipment. The test can be administered in a basic clinic or mobile screening unit by staff with minimal training.
It is also available in multiple pack sizes—1, 25, or 50 tests per box—which allows procurement to scale from pilot programs to population-level screening without changing suppliers. That flexibility matters when provincial health authorities are designing dementia screening protocols.
Why it matters:
China’s aging population is creating urgent demand for scalable, non-invasive screening tools. This test fits directly into that gap—provided real-world follow-up rates validate its positive predictive value in community settings.
View Product →
|
ScientificChina — tracking China’s science, technology, and industrial systems through the lens of real-world products.
Follow ScientificChina for deeper insight into the infrastructure behind global innovation.
Visit ScientificChina.
|
|
No products in the cart.